StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy

By Dr Frank Yap, M.D. -
August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair.


PCS consists of sequelae in one-third of COVID-19 patients and could potentially be permanent. The U.S. government estimated that between 7.7 to 23 million people are suffering from PCS in the United States. In Asia, PCS prevalence reaches 51%. Symptoms of PCS include breathlessness, persistent cough, fatigue, pain, brain fog, anxiety, depression, palpitations, dizziness, weakness, and sleep problems.

These symptoms have negative impacts on personal communication, daily activities, and social functioning. Some PCS sufferers even display severe disabilities. While a recent survey in the U.S. announced more than three-quarters of PCS patients did not feel sick enough to be hospitalized when infected with SARS-CoV-2, this impending health disaster is caused by a “silent killer” that seems determined to irreversibly destroy human health.

How this “silent killer” wreaks havoc on the body is still under investigation, as it appears SARS-CoV-2 viral infection is the current prospective mechanism leading to multiple organ damage. Moreover, this pathogenesis triggers long-term inflammation and autoimmunity. Therefore, although COVID-19 may be resolved in a patient, the remaining Long COVID symptoms become a chronic and systemic illness that leads to persistent PCS complications.

The prevention and treatment of COVID-19 is still challenged due to speedy mutations of SARS-CoV-2. Nevertheless, medical science has gradually identified keys to develop medicines to control infection. Hope remains in Pandora’s box as the hope to cure PCS-mediated disability is yet under development. There have been a few candidates for potential treatment or cure examined in clinical trials, but almost all may just temporarily ameliorate a specific PCS symptom. Treatment with systemic and persistent efficacy will be the total solution to cure PCS. StemCyte’s Phase II clinical trial aims to effectively treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair for long-term effect.

About StemCyte

StemCyte is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular therapies. It has operations in the United States, Taiwan, and India. The company has cooperated with more than 350 medical transplant centers around the world, and has successfully assisted in the treatment of more than 2,200 patients using cord blood transplants.

StemCyte considers umbilical cord blood banking its core competence, while actively pursuing new regenerative cell therapy indications, including spinal cord injury, Long COVID treatment, acute stroke, cerebral palsy and cancers. StemCyte’s mission is to continue to develop its unique cord blood banking capabilities to achieve the goal of delivering lifesaving therapies to patients who suffered degenerative and other life-threatening diseases.

References

  • Nalbandian A et al. (2021) Nature Medicine 27: 601-615.
  • Mehandru S et al. (2022) Nature Immunology 23: 194-202.
  • Huang L et al. (2022) The Lancet Respiratory Medicine doi: 10.1016/S2213-2600(22)00126-6.
  • Chen C et al. (2022) The Journal of Infectious Diseases doi: 10.1093/infdis/jiac136.
  • The New York Times. 2020-10-11 and 2022-05-08. 

Comments

Post a Comment

Popular posts from this blog

Dr Peter McCullough: How to Detox Spike Protein from Body

By Dr Frank Yap, M.D. -
Image
Base Spike Detox According to Dr Peter McCullough (in a Twitter post): Base Spike Detox is what I am currently using in my practice for those who have had COVID-19 multiple times, one or more of the COVID-19 vaccines, or both and believe persistent SARS-CoV-2 Spike protein could be causing problems in their body.  I have arrived, based on the emerging scientific literature (1) and my clinical observation, that three OTC products are essential as a triple base combination: Nattokinase 2000 FU (100 mg) twice a day Bromelain 500 mg once a day Nano/Liposomal Curcumin 500 mg twice a day Related: Nattokinase, Bromelain and Curcumin from The Wellness Company Additional products can be added, including NAC, IVM (Ivermectin), HCQ (Hydroxychloroquine), fluvoxamine, low-dose naltrexone, and blood thinners, depending on the clinical evaluation and the syndrome. The therapeutic...
Read more

Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (2024)

By Dr Frank Yap, M.D. -
Image
Dr. Peter McCullough is an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas, USA. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough Protocol 2022 Updates:  Double blind randomized controlled trial of saline solution gargling and nasal rinsing in COVID infection (Nov 2023) What really killed COVID-19 patients: It wasn't a cytokine storm, suggests study  (2023) Everyone is familiar with nasal and oral swab testing for COVID-19. It should be obvious the virus is replicating in the nose, and with Omicron, the speed of replication has become much greater than the pr...
Read more

How to Make Povidone Iodine 1% Nasal Spray (2024)

By Dr Frank Yap, M.D. -
Image
Is povidone iodine the next ivermectin or hydroxychloroquine? Is there any evidence that povidone iodine can treat COVID-19? Iodine 1% Nasal Spray is part of the FLCCC I-CARE early treatment protocol :  Nasal spray with 1% povidone-iodine: 2-3 times a day. Do not use for more than 5 days in pregnancy. If 1% product is not available, dilute the more widely available 10% solution and apply 4-5 drops to each nostril every 4 hours. Use 1 % povidone iodine commercial product as per instructions 2–3 x daily. If 1 %-product not available, must first dilute the more widely available 10 %-solution. To make 1% povidone iodine concentrated solution from 10% povidone iodine solution, one dilution method is as follows: – First pour 1½ tablespoons (25ml) of 10% povidone/ iodine solution into a nasal irrigation bottle...
Read more

Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments (2024)

By Dr Frank Yap, M.D. -
Image
Treatment should start based on clinical suspicion as soon as possible, preferably within the first 3 days of symptoms. Perform PCR testing, but do not withhold treatment pending results. 'Early' treatment will make significant difference in outcome as opposed to late treatment.  Related: How can I get Ivermectin? See the directory of professionals in US below. Directory of Doctors (by State) Prescribing Effective Outpatient COVID-19 Therapy USA ​ MULTIPLE STATES (Telemedicine or online consultation) The Wellness Company ( twc.health ) Medical Specialty: Family Medicine, Functional Medicine Supported Protocols: I-PREVENT (COVID Protection), I-CARE (Early at-home treatment), I-RECOVER (Long COVID and Post-Vaccine treatment) Dr. Miguel Antonatos (IVM) (855) 767-8559  https://text2md.com (States: AL, AZ, CO, FL, GA, IA, ID, IL, KS, KY, MD, ME, MI, MN, MS, ND, NE, NJ, NV, OK, SC, SD, TN, UT, VT, WA, WI, WV) ...
Read more

FLCCC I-Recover Protocol: Post Vaccine Treatment Protocol (2024)

By Dr Frank Yap, M.D. -
Image
Over the last three years, the COVID-19 pandemic has transformed almost every aspect of our lives before we've had time to stop and question it. Although no official definition exists for post-COVID-vaccine syndrome, a temporal correlation between a patient receiving a COVID-19 vaccine and beginning or worsening of clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes. Dr. Paul Marik and Dr. Pierre Kory are pleased to introduce the I-RECOVER: Post-Vaccine Treatment protocol, designed to help people who have experienced adverse symptoms after a COVID vaccine. Kory and Marik are both part of the FLCCC, which was founded in 2020 to share early treatment protocols for COVID-19. Kory is an ICU specialist, triple board certified in internal medicine, critical care and pulmonary medicine. He now runs a private tele-health practice specializing in the treatment ...
Read more

Dr Peter McCullough Early Treatment Protocol

By Dr Frank Yap, M.D. -
Image
Well-respected North Texas cardiologist, Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough et al. Reviews in Cardiovascular Medicine, 2020 McCullough Protocol 2022 Updates:  How to Detox Spike Protein from Body  (November 2023) Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2 (October 2024) Paxlovid for Vaccinated or Unvaccinated Adult Outpatients with ...
Read more

Front Line Doctors Ivermectin Protocol for Prevention and Treatment of COVID-19 (2024)

By Dr Frank Yap, M.D. -
Image
The Front Line COVID-19 Critical Care (FLCCC) Alliance was initially formed as a working group during the early COVID-19 pandemic days in response to multiple early reports of COVID patients with an inexplicably high need for prolonged mechanical ventilation and an excessive death rate.  Based on rapidly emerging clinical trials evidence, the FLCCC team has developed the   I-MASK+ protocol   ( is now divided into I-Prevent and I-Care protocols ) for prophylaxis and at home treatment of early stage COVID-19. Quercetin, zinc and a number of nutrients and drugs are part of this protocol, not only for critical care but also for prophylaxis and mild disease being treated at home. This article, we will dive deeper to provide the scientific background, related references and rationale of the FLCCC protocols. FLCCC ( Front Line COVID-19 Critical Care)  Protocols I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19 was designed for use as a prevention and...
Read more

Quercetin and Zinc: Zelenko Treatment Protocol

By Dr Frank Yap, M.D. -
Image
As of July 2024, more than 35 studies on the topic of zinc and COVID-19  ( c19zinc.com )  (constantly updated) and more than 10 studies on quercetin and COVID-19 have been published  ( c19quercetin.com ).  Dr. Zelenko’s main hypothesis based on the data showing that early intervention and treatment of high-risk patients with COVID-19 results in significantly few hospitalizations and deaths. This treatment regimen involving zinc, low-dose hydroxychloroquine, and azithromycin (published in the International Journal of Antimicrobial Agents ) is also apparently known as, “The Zelenko Protocol.” Quercetin and Zinc The Zelenko Covid-19 Protocols was developed by Dr Vladimir Zelenko. The protocol has as its centerpiece, but not exclusive piece, the combined use of  Hydroxychloroquine  (HCQ) and Zinc as a means by which a person can both help to prevent or mitigate the contraction of COVID-19, or can actually treat the disease once it has been diagno...
Read more

Dr Peter McCullough: Fact Check and Debunked Theories

By Dr Frank Yap, M.D. -
Image
Biography Well-respected North Texas cardiologist, Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. Personal History Dr. Peter A. McCullough was born in Buffalo, New York, on the 29th of December 1962. During high school, he and his family moved to Wichita Falls in Texas and later settled in Grapevine. He has lived and worked in various parts of the United States, including Washington and Michigan, and he now resides in Dallas, Texas. McCullough Protocol 2022 Dr Peter McCullough Early Treatment Protocol ...
Read more

FLCCC I-CARE COVID Treatment Protocol for Outpatients (2024)

By Dr Frank Yap, M.D. -
Image
Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Please be sure you are using the latest version of this protocol. Warning (anesthesia and surgery): Please notify your anesthesia team if you are using the followi...
Read more

Labels

Show more

Archive

Show more